| Entry |
|
|---|
| Name |
Amphetamine sulfate (USP);
Benzedrine (TN);
Evekeo (TN) |
|---|
| Product |
|
|---|
| Generic |
AMPHETAMINE SULFATE (Amneal Pharmaceuticals NY LLC), AMPHETAMINE SULFATE (Aurolife Pharma), AMPHETAMINE SULFATE (Bionpharma), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (Bryant Ranch Prepack), AMPHETAMINE SULFATE (DR. REDDY'S LABORATORIES), AMPHETAMINE SULFATE (Epic Pharma LLC), AMPHETAMINE SULFATE (Granules Pharmaceuticals), AMPHETAMINE SULFATE (Lannett Company), AMPHETAMINE SULFATE (Solco Healthcare US), AMPHETAMINE SULFATE (SpecGx LLC), AMPHETAMINE SULFATE (Sun Pharmaceutical Industries), AMPHETAMINE SULFATE (Wilshire Pharmaceuticals), EVEKEO (AZURITY PHARMACEUTICALS) |
|---|
| Formula |
(C9H13N)2. H2SO4
|
|---|
| Exact mass |
368.1770
|
|---|
| Mol weight |
368.49
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
|
|---|
| Remark |
| Product (DG00966): | D07445<US> D02074<US> |
| Product (mixture): | D11624<US> |
|
|---|
| Efficacy |
Stimulant (central) |
|---|
| Disease |
Narcolepsy [DS: H01293] Attention deficit disorder with hyperactivity [DS: H01895] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07234 | Neurotransmitter transporter inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N06 PSYCHOANALEPTICS
N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06BA Centrally acting sympathomimetics
N06BA01 Amfetamine
D02074 Amphetamine sulfate (USP) <US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Attention Deficit Hyperactivity Disorder Agents, Amphetamines
Amphetamine
D02074 Amphetamine sulfate (USP)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00966 Amfetamine
D02074 Amphetamine sulfate
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC6
SLC6A2 (NAT1)
D02074 Amphetamine sulfate (USP) <US>
SLC6A3 (DAT1)
D02074 Amphetamine sulfate (USP) <US>
SLC18
SLC18A2 (VMAT2)
D02074 Amphetamine sulfate (USP) <US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02074
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG00966 Amfetamine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 25
1 C8y C 21.4900 -16.1000
2 C8x C 20.3000 -15.4000
3 C8x C 21.4900 -17.5000
4 C1b C 22.6800 -15.4000
5 C8x C 19.0400 -16.1000
6 C8x C 20.3000 -18.2000
7 C1c C 23.9400 -16.1000
8 C8x C 19.0400 -17.5000
9 C1a C 25.1300 -15.4000
10 N1a N 23.9400 -17.5000
11 S4a S 30.3800 -16.6600
12 O1d O 30.3800 -15.2600
13 O1d O 30.3800 -18.0600
14 O1d O 31.7800 -16.6600
15 O1d O 28.9800 -16.6600
16 C8y C 21.4900 -16.1000
17 C8x C 20.3000 -15.4000
18 C8x C 19.0400 -16.1000
19 C8x C 19.0400 -17.5000
20 C8x C 20.3000 -18.2000
21 C8x C 21.4900 -17.5000
22 C1b C 22.6800 -15.4000
23 C1c C 23.9400 -16.1000
24 C1a C 25.1300 -15.4000
25 N1a N 23.9400 -17.5000
BOND 24
1 11 12 2
2 11 13 2
3 11 14 1
4 11 15 1
5 1 2 2
6 1 3 1
7 1 4 1
8 2 5 1
9 3 6 2
10 4 7 1
11 5 8 2
12 7 9 1
13 7 10 1
14 6 8 1
15 16 17 2
16 16 21 1
17 16 22 1
18 17 18 1
19 21 20 2
20 22 23 1
21 18 19 2
22 23 24 1
23 23 25 1
24 20 19 1
BRACKET 1 18.4800 -19.2500 18.4800 -14.3500
1 26.6700 -14.3500 26.6700 -19.2500
1 2
ORIGINAL 1 1 2 5 8 6 3 4 7 9 10
REPEAT 1 16 17 18 19 20 21 22 23 24 25
|
|---|
